Advanced research platforms targeting high-unmet medical needs across oncology, immunology, neurology, rare diseases, and precision medicine. Explore our active programs and collaborative pathways.
First-in-class KRAS G12C inhibitor with dual MET modulation. Demonstrating robust tumor regression in NSCLC and pancreatic adenocarcinoma cohorts.
Selective JAK3/TEC inhibitor for rheumatoid arthritis and lupus nephritis. Engineered for peripheral tolerance preservation and reduced cytokine storm risk.
BBB-penetrant antisense oligonucleotide targeting tau hyperphosphorylation pathways. Early biomarker reduction observed in AD and PSP models.
AAV9-mediated SMN1 gene replacement with next-generation capsid engineering. Longitudinal motor function improvement sustained at 18-month follow-up.
Allogeneic TCR-engineered T-cells with safety switch and homing chemokine receptors. Targeting solid tumor microenvironment immune suppression.
Dual GIP/GLP-1 receptor agonist with extended half-life formulation. Addressing insulin resistance, hepatic steatosis, and cardiovascular risk factors.
Oral nucleoside analog with pan-coronavirus and paramyxovirus activity. Novel polymerase exoN bypass mechanism enabling high barrier to resistance.
CRISPR-based epigenetic editor for retinitis pigmentosa. Non-integrating delivery vector preserving endogenous photoreceptor gene expression profiles.
Proprietary deep learning models analyzing multi-omics datasets to identify novel therapeutic targets with validated disease-modifying potential.
Lipid nanoparticle engineering, viral capsid optimization, and antibody-drug conjugate platforms enabling precise tissue tropism and reduced off-target toxicity.
Automated cell line development, continuous biomanufacturing, and real-time quality control for rapid scale-up from discovery to commercial supply.
Explore co-development agreements, clinical trial partnerships, or technology licensing opportunities across our therapeutic portfolio.